MYmAb Biologics is a trusted tissue microarray company (https://www.mymab.com.my/) providing high-quality human tissue microarrays (TMAs) for both clinical and research applications. With a strong commitment to ethical sourcing, rigorous quality standards, and reliable global distribution, MYmAb Biologics supports researchers worldwide in advancing translational research and oncology studies using clinically relevant human tissue samples.
Dr Chua Jia Xin, founder of MYmAb Biologics, has been recognised as the National Young Scientist Award 2025 recipient in the Medical category, highlighting Malaysia’s growing strength in biotechnology talent. Dr Chua has built a reputation for pioneering therapeutic monoclonal antibody development, translating research into therapies that directly target and eliminate cancer cells. One of her UK-developed antibodies has already been licensed for clinical exploration, showcasing the global relevance and impact of her work.
Her mission is to make advanced antibody-based therapies more accessible and affordable for Malaysian patients, reducing reliance on costly imported biologics while elevating the country’s presence in the international biotherapeutics sector. Under her leadership, MYmAb Biologics has also become a trusted provider of tissue microarrays, empowering local and regional scientists with high-quality research tools for oncology and biomarker studies.
Dr Chua’s award reflects her scientific excellence and dedication to real-world impact, ensuring that discoveries lead to practical clinical applications and patient benefit. Her achievement joins those of this year’s other distinguished award recipients, collectively representing a new generation of Malaysian scientists shaping the future of science, technology, and innovation.
To learn more about MYmAb Biologics and its tissue microarray solutions, visit the MYmAb Biologics website.
This news article is provided and written by Pillars Media (https://pillarsmedia.my/).
